 |
|
|
| |
Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy:
Latest Results From the German Hepatitis C-Registry
|
| |
| |
Reported by Jues Levin
ID Week 2018, October 3-7, 2018, San Francisco, California
J Reimer1,2, A Stoehr3, U Naumann4, G Teuber5, C Zamani6, S Mauss7, N Qurishi8, K Lohmann9, H Kleine9, A Pangerl9, S Christensen10
1Gesundheit Nord - Bremen Hospital Group, Bremen, Germany; 2Center for Interdisciplinary Addicti on Research University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3ifi -Insti tute for Interdisciplinary Medicine, Hamburg, Germany; 4Praxiszentrum Kaiserdamm, Berlin, Germany; 5Practi ce PD Dr. med. G. Teuber, Frankfurt am Main, Germany; 6Practi ce Dr. med. C. Zamani, Hannover, Germany;
7Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 8Gemeinschaft spraxis Gotenring, Cologne, Germany; 9AbbVie Inc., North Chicago, Illinois, United States; 10CIM Munster, Munster, Germany
|
| |
|
|
|
|
|
